ABL1 and acute lymphoblastic leukemia: Additionally, the SJCRH Total therapy XVII study (NCT03117751), started in 2017, explored the effect of adding dasatinib from day 15 of induction to all patients with ABL-class fusion positive ALL identified by RNA-seq, regardless of the patient’s MRD level [97].